Plasma Exchange: The Next Longevity Breakthrough or Just Costly Hype?

DENVER, CO – March 27, 2026 – A procedure traditionally used to treat severe autoimmune disorders is now being offered in Colorado as one of the latest frontiers in the quest for a longer, healthier life. ThriveMD, a Denver-area concierge clinic, has announced it will provide Therapeutic Plasma Exchange (TPE) as a premier longevity intervention, promising a “deep reset for the global biologic system.”

The treatment, which involves filtering a patient's blood plasma to remove harmful substances, is being marketed to reduce inflammation, improve cognitive clarity, and even clear environmental toxins. It represents a significant step for a medical technique moving from the confines of acute hospital care into the booming private market for anti-aging and wellness.

“TPE is a truly transformative procedure,” said Meghan Herwehe, CEO of ThriveMD’s parent company, Novellum Longevity, in a recent press release. “As the premier longevity medical practice in Colorado, we're thrilled to lead in the next wave of clinical innovation and help patients access such state-of-the-art care.”

The Science of a System Reset

At its core, Therapeutic Plasma Exchange is a filtration process. A patient’s blood is drawn and separated into its components. The plasma—the liquid portion carrying proteins, antibodies, and other substances—is removed and replaced with a substitute fluid, typically a saline and albumin solution, before the blood is returned to the body. For decades, this has been a frontline or secondary treatment for a range of life-threatening conditions like Guillain-Barré syndrome and Myasthenia gravis, where the goal is to remove rogue antibodies or toxic proteins.

The new application for longevity hinges on a similar principle: that the aging process is accelerated by the accumulation of harmful factors in the blood. Proponents argue that TPE can remove pro-aging factors, inflammatory proteins, and metabolic byproducts associated with what is known as “inflammaging”—the chronic, low-grade inflammation linked to aging.

This theory received a significant boost from a recent study by the Buck Institute for Research on Aging, published in the journal Aging Cell. The research, conducted in collaboration with Circulate Health, found that TPE treatments reduced participants' biological age—a measure of health at the cellular level—by an average of 1.32 years. When combined with intravenous immunoglobulin (IVIG), the effect was more pronounced, showing a reduction of 2.61 years. The study pointed to improvements across the epigenome, proteome, and immune system.

However, experts caution that the science is still in its infancy. The Buck Institute study was groundbreaking but had a small number of participants, and its authors noted the benefits were short-term, suggesting the body may have compensatory mechanisms that blunt the anti-aging effects over time. The need for larger, long-term human trials is a recurring theme among independent researchers in the field.

A New Hope or Unproven Promise?

For patients grappling with complex chronic illnesses, the line between hope and hype can be thin. ThriveMD’s announcement lists TPE as a supportive treatment for a host of challenging conditions, including Multiple Sclerosis, certain lymphomas, and neurodegenerative diseases like Alzheimer's. The clinic is careful to state that TPE is not a cure but can help alleviate symptoms and enhance the effectiveness of other treatments.

The procedure itself is a significant commitment, with sessions lasting three to four hours. While generally considered safe when using an albumin replacement fluid, it is not without risks. Patients can experience temporary side effects like fatigue or low blood pressure. More serious complications, though rare with modern protocols, can occur.

Beyond its established uses, the expansion of TPE into the wellness space raises questions about its off-label application. The U.S. Food and Drug Administration (FDA) regulates the medical devices used for TPE but does not approve the procedure for specific indications. Its use for general longevity, cognitive enhancement, or to “clear microplastics,” as claimed by some clinics, is not an FDA-approved application. The claim regarding microplastic removal, in particular, lacks substantial support in prominent scientific literature concerning human treatment, with most research focused on environmental filtration methods.

“The evidence for TPE in established autoimmune diseases is robust,” commented one immunologist not affiliated with the clinic, who spoke on the condition of anonymity. “But applying it for general ‘longevity’ is a major leap. We need to see data from large, controlled trials before we can say with any certainty that the benefits outweigh the costs and potential risks for healthy individuals.”

The Booming Business of Living Longer

ThriveMD’s strategic move places it squarely within a competitive and rapidly expanding market for high-end longevity medicine. The clinic, founded by Dr. Scott Brandt, positions itself as a premier provider of regenerative and concierge services, and the addition of TPE is a clear effort to solidify that standing. It joins a growing number of practices across the country offering similar services, often at a steep price.

National players like Circulate Health, which operates in dozens of clinics, and specialized centers such as MaxWell Clinic in Nashville and Aether Medicine in Pennsylvania, are already marketing TPE as a cornerstone of their anti-aging protocols. Session costs can run into the thousands of dollars, placing this intervention firmly in the realm of concierge medicine, accessible primarily to the wealthy.

In Colorado, ThriveMD competes with other centers focused on anti-aging and regenerative medicine, each vying for a share of a clientele eager to invest in optimizing health and extending lifespan. This trend reflects a broader shift in healthcare, where proactive, personalized wellness is becoming a luxury commodity.

As clinics continue to push the boundaries of what is possible in medicine, offering cutting-edge treatments that often outpace regulatory approval and long-term scientific consensus, the onus falls on consumers. Navigating this new landscape requires a careful balance of optimism, skepticism, and a thorough evaluation of both the potential promise and the scientific evidence supporting it.